N eutrophil responses are a critical element in host defense during bacterial infections, for example, but neutrophil responses can also be overtly pathogenic. Thus, during many inflammatory diseases, neutrophils contribute more to the pathology than do the microbes themselves (1) . Neutrophil recruitment is a complex process involving activation of local structural cells (e.g., epithelial cells) via pathogen-associated molecular pattern receptors, complement cascade products, or arachidonic acid metabolites, such that the structural cells express inflammatory mediators (e.g., IL-1, CXCL8) (2) . These can in turn activate regional endothelial cells, which actively foster intravascular neutrophil retention via the now classical paradigm of chemokine (e.g., CXCL8)-and adhesion molecule-mediated rolling-arrest diapedesis (3, 4) .
The ELR-CXC chemokines are a subgroup of the CXC chemokine family in which the amino subterminal two cysteine residues, which are separated by an alternate amino acid, are immediately preceded by a Glu-Leu-Arg motif. They include CXCL1-3 and 5-8 (growth-related oncogene ␣, ␤, and ␥; epithelial cell neutrophil-activating peptide-78; granulocyte chemotactic protein-2; neutrophil-activating peptide-2; and IL-8, respectively) (3), which chemoattract and activate neutrophils via two closely related G protein-coupled receptors (GPCR), 3 the CXCR1 and CXCR2. CXCL8 binds both receptors with high affinity, whereas CXCL6 binds both receptors with lower affinity (5, 6) . The other ELR-CXC chemokines bind to the CXCR2, also with relatively lower affinities (6, 7) . Both the CXCR1 and CXCR2 can trigger chemotactic responses and intracellular Ca 2ϩ flux in neutrophils and contribute to elastase release (6, 8) , but activation of the respiratory burst and phospholipase D release responses is reportedly CXCR1 dependent (9) , whereas CXCR2 signaling is critical to matrix metalloproteinase (MMP)-9 release (10) . Moreover, these two receptors may be differentially involved in neutrophilic pathology in vivo. For example, the CXCR1 is reportedly of more importance in inflammatory bowel diseases (11) , sepsis, and acute respiratory distress syndrome (12, 13) , whereas both it and the CXCR2 play roles in synovial infiltration by neutrophils in arthritic joints (14) . However, numerous alternate GPCR are involved in neutrophilic inflammation, including those for leukotriene B 4 (LTB 4 ), C5a, and fMLP, such that antagonism of either LTB 4 or C5a has been shown to be of significant benefit in various inflammatory settings (15) (16) (17) . The precise interrelationships of these mediators in inflammatory responses have not been formally determined, but it has been reported that signaling through the C5a or fMLP receptors can effectively desensitize the ELR-CXC chemokine receptors (18) . In contrast, CXCL8 reportedly poorly desensitizes some events (e.g., intracellular Ca 2ϩ flux) associated with C5a and fMLP receptor signaling (19, 20) , although it can desensitize chemotactic responses driven by these ligands (18) .
Some time ago, we developed a very high-affinity broad-spectrum ELR-CXC chemokine antagonist, bovine CXCL8 K11R/ G31P (bG31P) (21, 22) , based on a high-affinity bovine CXCL8 analog, CXCL8 K11R (23) . This antagonist could block CXCL8 binding to neutrophils, as well as neutrophil activation by agonists present in wash fluids from the lungs of cattle with bacterial pneumonia. bG31P fully antagonizes neutrophil responses to endotoxin challenge of cattle for more than 2 days after a single low-dose treatment (22) , and blocks pyrexia, hemorrhagic consolidation, and pulmonary neutrophilia in airway endotoxemia in guinea pigs even if delivered after the onset of symptoms (24) . We also subsequently developed numerous human-bovine chimeric forms of bG31P that were as effective as bG31P in blocking ELR-CXC chemokine-mediated pathology (25) , and then developed a fully human form of G31P. However, some of the protective effects of bG31P in airway endotoxemia (24) , for example, seemed to be somewhat tangentially related to its putative neutrophil-centered effects. For example, bG31P treatment reduces endogenous pyrogen expression and pyrexia before the time when neutrophils were appreciably present in the airways, suggesting that it may have effects on structural (e.g., epithelial) cells. Moreover, data from a study of the effects of G31P in aspiration pneumonia, wherein high-level bacterial colonization of the lungs occurs, confirmed its effectiveness in this environment as well (X. Zhao, J. Town, and J. Gordon, submitted for publication). In such cases, the bacteria would release formyl peptides (e.g., fMLP) among other products and activate the complement cascade, leading to the generation of C5a.Thus, we wished to explore further the mechanisms by which G31P might interact with airway epithelial cells, but also its effect on neutrophil responses to ligands for heterologous GPCR.
Materials and Methods

Reagents and supplies
The following reagents were purchased commercially: restriction endonucleases BamHI and EcoRI, T4 DNA ligase, DNA polymerase, fluo-4 AM, MEM (with L-glutamine), HEPES, lipofectamine 2000, and MEM nonessential amino acid solution (Invitrogen); QIAprep Spin Miniprep, QIAquick Gel Extraction Kits, QIA shredder, and RNeasy Mini Kit (Qiagen); QuickChange Site-Directed Mutagenesis Kit and Brilliant qRT-PCR Master Mix Kit (Stratagene Cloning Systems); glutathione-Sepharose, the expression vector pGEX-2T, and benzamidine-Sepharose (Amersham Biosciences); aprotinin, dextran, endotoxin (Escherichia coli LPS, serotype 0127:B8), hexadecyltrimethylammonium bromide, gelatin, isopropyl-thio-D-galactopyranoside, luminol, phenol red-free HBSS, PMSF, tetramethylbenzidine, Triton X-100, and DTT (Sigma-Aldrich); paired anti-CXCL8 capture and detection Abs and rCXCL8 (R&D Systems); rabbit anti-human lactoferrin Ab, recombinant lactoferrin, and biotinylated anti-lactoferrin Ab (ICN Biomedicals); Lymphocyte Separation Medium density gradient medium (MP Biomedicals); Diff-Quick stain kit (American Scientific Products); annexin V/propidium iodide staining kit (BD Biosciences); and 5-wk-old female Hartley guinea pigs (Charles River Laboratories). All of the experiments were conducted according to the guidelines established by the Canada Council on Animal Care, and were approved by University of Saskatchewan animal ethics review panel.
Generation of G31P
A full-length human CXCL8 cDNA was synthesized commercially (Takara Biotech). From this, we generated a GST fusion protein construct encoding aa 3-72 of human CXCL8, then introduced a Lys 11 -to-Arg substitution (we reported previously that bovine CXCL8 K11R is a very high-affinity CXCR1/CXCR2 agonist) (23) . We next introduced a Gly 31 to Pro substitution, to generate human CXCL8 K11R/G31P (G31P). Each plasmid was transformed into competent HB101 cells, and their sequences were verified commercially (Plant Biotechnology Institute). The methods for expressing the constructs, cleaving the target proteins from their GST fusion partners, and purifying these have been described in detail (21, 22) . Briefly, the recombinant bacteria were sonicated in the presence of the protease inhibitors aprotinin (2 mg/ml) and PMSF (50 mM), and then the rGST fusion proteins present in the sonicates were purified by affinity chromatography using glutathione-Sepharose columns. The rCXCL8 analogues were cleaved from their GST fusion partners by thrombin digestion and then further purified using benzamidine-Sepharose columns. The relative molecular mass and purity of each protein were verified by SDS-PAGE and Western blotting with biotinylated anti-human CXCL8 Ab (21, 23) .
Generation of CXCR1-transfected HEK293 cells
HEK293 cells (CRL-1573; American Type Culture Collection) were transfected with the gene for the CXCR1 in the vector pCDNA3.1 ϩ (Missouri S&T cDNA resource center; www.cdna.org) using lipofectamine. The CXCR1-expressing cells were selected using gentamicin (800 g/ml), and their expression of the CXCR1 gene was confirmed by FACS and quantitative real-time PCR.
Chemotaxis assays
Chemotaxis was assessed using modified Boyden chamber microchemotaxis assays (21-23) with either purified neutrophils or CXCR1-transfected HEK cells. For the former, human peripheral blood leukocytes were fractioned on standard density gradients, and the neutrophils were harvested from the bottom of the gradients and cleared of contaminating RBC by hypotonic lysis. The purified neutrophils (or HEK cells) were suspended at 2 ϫ 10 6 /ml in PBS ϩ (pH 7.4) (1.2 mM MgCl 2 , 5 mM KCl, 0.5 mM CaCl 2 , 5 mM glucose, and 0.1% BSA). The chemoattractants (e.g., CXCL8), either alone or together with G31P, were placed in the bottom compartment of the Boyden chamber wells and cells in the upper compartment, with the two compartments separated by polyvinylpyrrolidone-free, 5 (neutrophils)or 10 (CXCR1-HEK cells)-m pore-size polycarbonate filters. After incubation for 20 min (neutrophils) or 5 h (CXCR1-HEK cells) at 37°C in a 5% CO 2 atmosphere, the cells that had migrated into the filters were fixed and stained using a Diff-Quick kit. The numbers of cells responding in each well were enumerated by direct counting of at least five ϫ40 objective fields, and the results were expressed as the mean number of cells per ϫ40 field Ϯ SEM.
In a series of preliminary experiments, we confirmed that CXCL1, CXCL5, and CXCL8 induced maximal neutrophil chemotactic responses at concentrations of 100, 100, and 10 ng/ml, respectively, whereas CXCL8 induced maximal CXCR1-HEK cell responses at 100 ng/ml. We also optimized the dilution of each sputum sample (i.e., 1:1 to 1:100) required to maximize its neutrophil chemotactic activity. We tested the effects on sputum-induced chemotactic responses of using G31P at 0.1-100 ng/ml, and found that the antagonistic effects observed at 10 ng/ml were not altered by increasing the dose of G31P (data not shown).
Reactive oxygen intermediate (ROI) release assay
We used total white blood cell (WBC) preparations for the ROI release assays. To generate WBC, heparin-anticoagulated human blood was mixed with an equal volume of 6% (w/v) dextran (75 kDa) in PBS, and then the tubes were allowed to stand upright and undisturbed for Ϸ1 h at room temperature. When the RBC had sedimented, the upper phase, comprising plasma, platelets, and WBC, was centrifuged and the cell pellet was resuspended at 2.5 ϫ 10 6 cells/ml HBSS. For the assays, we mixed 50 l of WBC, 25 l of human CXCL8 (final concentration, 100 ng/ml) or HBSS, 25 l of HBSS or the indicated concentrations of G31P, and 50 l of luminol (0.3 mM). We had confirmed in preliminary experiments that 100 ng/ml CXCL8 was optimal for induction of WBC ROI release, as determined by chemiluminescence using a microplate spectrofluorimeter (NovoStar; BMG LABTECH). The data are expressed as the maximum sample luminescence minus that of cells exposed to HBSS alone.
Assay of intracellular Ca 2ϩ flux
Neutrophils were purified, as described above, and then washed twice with Ca 2ϩ -free PBS ϩ medium and suspended at 5 ϫ 10 6 cells/ml in the same medium. The cells were stained for 30 min at 37°C with 2 M fluo-4 AM, and then washed twice with Ca 2ϩ -free PBS ϩ , resuspended at 4 ϫ 10 6 cells/ml in PBS ϩ containing 3.3 nM Ca 2ϩ , and kept at room temperature until used for testing. Before challenge, the cells were incubated for 15 min with medium or G31P (100 ng/ml), and then challenged with medium or human CXCL1, CXCL5, or CXCL8 (each, 100 ng/ml). In preliminary experiments, we had confirmed that 100 ng/ml induced optimal intracellular Ca 2ϩ flux in these cells, as determined using a microplate spectrofluorimeter (emission wavelength, 520 nm; excitation wavelength, 488 nm).
Heterologous desensitization of GPCR
Neutrophils were purified, as above, resuspended in PBS ϩ medium at 2 ϫ 10 6 cells/ml, and then stimulated with 0.1 nM C5a, 1 nM fMLP, or 1 ng/ml LTB 4 in the presence of 0, 10, or 50 ng/ml G31P. The impact of the G31P on the agonist-induced intracellular Ca 2ϩ flux and chemotactic responses was measured, as noted above. These experiments were repeated three times.
Sputum samples
Sputum samples were collected for diagnostic purposes from 12 cystic fibrosis (CF) or bronchiectasis patients with bacterial pneumonia. Sputa from two subjects with chronic obstructive pulmonary disease (COPD) or asthma were also obtained as controls. For processing, the sputum mucus plugs were dispersed by treatment with 1% DTT/HBSS, and then the cells were sedimented and the supernatants were dialyzed extensively against multiple changes of PBS, as noted previously (26 -28) . The levels of CXCL8 in each sample were determined by ELISA, as noted (26) . The supernatants were aliquoted and stored at Ϫ80°C. Sputum from healthy donors did not induce any significant neutrophil chemotactic responses (data not shown).
Effects of G31P on responses of A549 bronchial epithelial cells
Human A549 bronchial epithelial cells (American Type Culture Collection CCL185) were grown to a maximum of 90% confluence in 24-well plates in MEM (with L-glutamine) supplemented with 10% FBS, 0.01 M HEPES, and nonessential amino acids. Before stimulation, the cell monolayers were washed and provided with fresh medium, and then exposed for 15 min at room temperature to 1-100 ng/ml G31P. The indicated doses of LPS or 0 -1.28 ϫ 10 6 unstimulated purified neutrophils from healthy donors were added to the cells, which were incubated for 16 h at 37°C before the supernatants were collected. Total RNA was collected from the cells using commercial extraction kits and standard approaches. ELISA were used to quantify cytokine levels in the supernatant fluids, whereas quantitative realtime PCR was used to quantify the relative mRNA levels.
ELISA of cytokines and chemokines
Our ELISA protocols have been reported in detail previously (26) . Culture supernatants were not diluted before the assays, whereas bronchoalveolar lavage (BAL) fluids for lactoferrin assays were diluted 1/10. The data are presented as pg/ml or ng/ml, based on recombinant protein standard curves. The cytokine ELISAs were sensitive to 5-10 pg/ml, whereas the lactoferrin assay was sensitive to 5 ng/ml. Our CXCL8 ELISA does not detect G31P, because the capture Ab does not recognize this molecule (J. R. Gordon, unpublished observation).
Quantitative real-time PCR
Total cellular RNA was quantified spectrophotometrically and stored at Ϫ80°C. For quantitative real-time PCR, we used a commercial one-step master mix kit, with the thermal profile programmed as follows: first segment, 50°C for 30 min, and 95°C for 10 min (1 cycle); second segment, 95°C for 30 s, 62°C for 30 s, and 72°C for 30 s (40 cycles); and third segment, the reading was taken at 72°C during the 30-s plateau. The sequences of the quantitative real-time PCR primers were as follows: GAPDH forward, 5Ј-TGC CTC CTG CAC CAC CAA C-3Ј and reverse, 5Ј-GGC CAT CCA CAG TCT TCT GG-3Ј; CXCL1 forward, 5Ј-CCC AAG AAC ATC CAA AGT GTG A-3Ј and CXCL1 reverse, 5Ј-GTC ACT GTT CAG CAT CTT TTC G-3Ј.
Neutrophil apoptosis
Human neutrophils were isolated, as described above, resuspended at 5 ϫ 10 6 cells/ml in PBS ϩ , and then aliquoted into 96-well plates at 100 l/well. Medium (PBS ϩ ) alone or containing G31P (100 ng/ml) was added to the cells and incubated for 15 min at room temperature, before addition of CXCL1 or CXCL8 (100 ng/ml) or carrier medium alone. After 24 h at 37°C, the cells were stained as per the manufacturer's instructions using FITC-labeled annexin V and propidium iodide for FACS detection of apoptotic and necrotic cells, respectively, and then analyzed within 1 h using a FACScan flow cytometer.
In vivo confirmation of the anti-inflammatory activities of G31P
The assessment of the effect of G31P on 15-h airway endotoxemia pathology in guinea pigs has been described previously for the bovine and human-bovine chimeric forms of G31P (24, 25) . Briefly, for challenge the animals (n ϭ 5) were given a 200-l bolus of LPS (5 g/kg) in sterile saline by intranasal intubation. At 30 min before challenge, 250 g/kg G31P or an equivalent volume (1 ml) of saline was given s.c., and at 4, 8, or 16 h postchallenge the animals were euthanized with halothane. BAL was collected using 2.0-ml vol of sterile saline. BAL total WBC and RBC were enumerated by direct counting, and the results were expressed as the mean number of cells per BAL sample (ϮSEM). BAL cell differentials were determined using Wright's solution-stained BAL cell cytospin preparations, and the total numbers of neutrophils were calculated using these data. All of the data are expressed as means Ϯ SEM. All BAL fluids were assessed independently (either immediately or after storage at Ϫ80°C) for myeloperoxidase (MPO), MMP-9, MMP-2, and lactoferrin (LF). This experiment was repeated twice.
MPO assay
BAL fluids (10 l) were diluted 10-fold with 0.5% hexadecyltrimethylammonium bromide and incubated at room temperature for 10 min with 10 vol of tetramethylbenzidine, before stopping the reactions with 10 vol of 1 M phosphoric acid. The reactions were quantified by spectroscopy (OD, 450 nm), and the data were expressed as the mean OD 450 Ϯ SEM. Each sample was assayed in triplicate.
Assessment of BAL MMP-9 and MMP-2 levels
BAL levels of MMP-2 and MMP-9 were measured by gel zymography, as previously described (10) . Briefly, 20-l samples of BAL sample were run on 7.5% SDS-PAGE gels containing 1 mg/ml gelatin. The gels were incubated overnight at room temperature in 2.5% Triton X-100, 50 mM Tris-HCl, 10 mM calcium chloride, and 1 mM zinc chloride; rinsed in deionized water for 30 min; and then incubated overnight at 37°C in 50 mM Tris-HCl, 10 mM calcium chloride, and 1 mM zinc chloride, before staining with Coomassie brilliant blue. The identities of the gelatinolytic MMP-2 and MMP-9 bands were determined based on their molecular weights and comparison with standards prepared from homogenates of untreated HT1080 fibrosarcoma cells (American Type Culture Collection CCL21) (29) . The results are expressed as relative densitometry units for each gelatinase band.
Statistical analysis
Two-group comparisons were made using Student's t tests (two tailed). We used Spearman Rank correlation analyses to assess the correlations between the sputum cytokine levels and their associated responses. All results are expressed as the mean Ϯ SEM.
Results
Human CXCL8 
K11R/G31P effectively antagonizes both CXCR1-and CXCR2-dependent activation of neutrophils
To confirm unequivocally whether human CXCL8 K11R/ G31P (G31P) acts at least in part through the CXCR1, we used CXCR1-transfected HEK293 cells. We confirmed by FACS (data not shown) and quantitative real-time PCR (Fig. 1A ) that these cells express this receptor, but not the CXCR2 (data not shown), and that 100 ng/ml CXCL8 induced chemotactic and intracellular Ca 2ϩ flux responses. At 10 ng/ml, G31P Ϸ80% blocked CXCL8induced chemotactic responses, whereas at 100 ng/ml (but not 10 ng/ml; data not shown) it dramatically reduced intracellular Ca 2ϩ flux (Fig. 1A) . Given the biological differences between CXCR1transfected HEK cells and neutrophils, we also confirmed with freshly purified human neutrophils that G31P blocked CXCL8 (10 ng/ml)-induced chemotaxis and ROI release ( Fig. 1B) . It is noteworthy that neutrophil superoxide release is reportedly attributable exclusively to CXCR1 signaling (15) . We also found that 10 ng/ml G31P markedly attenuated intracellular Ca 2ϩ flux induced by 100 ng/ml CXCL8 (Fig. 1B) . We then assessed the ability of G31P to block activation of neutrophils induced by CXCR2-exclusive ligands. As with CXCL8, G31P dose dependently blocked chemotactic responses of neutrophils to CXCL1 and CXCL5 (both 100 ng/ml), whereas 10 ng/ml G31P Ն95% reduced intracellular Ca 2ϩ flux induced by an optimal dose (100 ng/ml) of either ligand (Fig.  1C ). It is noteworthy that, overall, CXCL8 was a substantially stronger agonist than either CXCL1 or CXCL5 in terms of inducing this intracellular Ca 2ϩ response.
G31P induces heterologous desensitization of alternate GPCR
Numerous neutrophil agonists, including C5a, LTB 4 , ELR-CXC chemokines, and fMLP, signal into these cells via distinct GPCR.
It has been shown previously that signaling through C5a, fMLP, or CXCL8 can reciprocally desensitize neutrophil chemotactic responses to subsequently introduced heterologous ligands (18) . In contrast, CXCL8 reportedly does not effectively desensitize C5aor fMLP-induced neutrophil activation as assessed by intracellular Ca 2ϩ flux (19, 20) . In assessing the relative capacity of G31P to affect heterologous GPCR signaling, it is important to recognize that G31P has a much higher affinity for its receptors than do the ELR-CXC chemokines. Thus, bG31P inhibits by 50% the chemotactic responses of neutrophils to a Ϸ250-fold higher concentration of native ligand (i.e., CXCL8) (22) . We wished to assess then the extent to which G31P would desensitize neutrophil responses to ligands such as C5a, fMLP, and LTB 4 , each of which are relevant neutrophil agonists in inflammatory conditions. Thus, we examined the impact of G31P on intracellular Ca 2ϩ flux and chemotactic responses induced by each of these agonists (Fig. 2 ). We found that 0.1 nM C5a induced marked Ca 2ϩ flux in neutrophils, as well as chemotactic responses, and that the addition of G31P reduced C5a-mediated chemotaxis by Ն50%, although its impact on intracellular Ca 2ϩ flux was substantially more modest. The bacterial tripeptide fMLP induced a much more robust Ca 2ϩ flux response than did C5a, but an essentially equivalent chemotactic response. The G31P treatment very substantially reduced both the Ca 2ϩ and chemotactic (85% reduction) responses. LTB 4 was a strong neutrophil agonist in both assays and, as with fMLP, G31P substantially reduced LTB 4 -induced Ca 2ϩ flux and chemotactic (Ϸ67% reduction) responses. Taken together, these data show that G31P did dampen neutrophil responses to each of these heterologous GCPR ligands.
G31P effectively antagonizes the inflammatory mediators present in sputum from bacterial pneumonia patients
As suggested above, inflammatory diseases are marked by the simultaneous expression of numerous neutrophil agonists. Sputum from CF patients, for example, can contain CXCL8 and other CXC chemokines, LTB 4 , formyl peptides (e.g., fMLP), and perhaps C5a (30) . Thus, given our data documenting that G31P can variably desensitize these receptors, we wished to know just how effective it would be in blocking the agonists present in inflammatory samples. Thus, we obtained a bank of sputa from 12 CF and bronchiectasis patients being treated for bacterial pneumonia and directly tested the impact of G31P on their neutrophil chemotactic activities (Fig. 2) . The disease status of the CF donors was classified as advanced, severe, moderate, or mild, and that of the bronchiectasis donors as severe or moderate, or frank bacterial pneumonia, based on clinical criteria. We included sputum from one asthmatic and one COPD subject as controls. We assessed the levels of CXCL8 in each sputum sample ( Fig. 3 ; values above the sample bars) and found that these correlated positively with the ability of the samples to induce neutrophil chemotaxis (r ϭ 0.63 (14 degrees of freedom), p ϭ 0.013). At 10 ng/ml G31P, Ϸ60 -95% inhibited the chemotactic responses of neutrophils from healthy blood donors to the sputum from 10 of the 12 CF and bronchiectasis donors. Only sputum from the two donors classified as having advanced CF (donors 1 and 2) appeared more or less resistant to the antagonistic effects of G31P in this assay. Interestingly, the relative ability of G31P to block sputum-induced neutrophil chemotactic activities (i.e., percentage of inhibition) was not significantly correlated with the levels of CXCL8 in the samples (r ϭ 0.369 (14 df), p ϭ 0.15). For example, sample 1 contained 3.09 ng/ml CXCL8 and was only modestly affected by G31P, whereas sample 10 contained 3.32 ng/ml CXCL8 and its activity was almost ablated by the G31P treatment. The sputum from FIGURE 1. The ELR-CXC chemokine antagonist CXCL8 K11R/ G31P operates by targeting the CXCR1 and CXCR2 on neutrophils. A, We generated CXCR1-transfected HEK293 cells and used these to determine whether G31P acts via the CXCR1. We used quantitative real-time PCR to assess CXCR1 expression by control and CXCR1-transfected HEK cells and compared this expression with that of peripheral blood neutrophils (left panel). For the chemotaxis assays, responses to an optimized concentration of CXCL8 (10 ng/ml) were assessed using modified Boyden chamber microchemotaxis assays, as noted in Materials and Methods. The ability of G31P (10 ng/ml) to antagonize this response was assessed by simultaneously exposing the cells to the agonist and antagonist. The results are expressed as the mean (ϮSEM) number of cells/ϫ40 objective microscope field (middle panel). For the Ca 2ϩ flux assays, neutrophils were labeled with the Ca 2ϩ indicator dye fluo-4 AM and assayed in the presence (100 ng/ml) or absence of G31P for chemokine (100 ng/ml)-induced intracellular Ca 2ϩ flux, as described in Materials and Methods (right panel). B, We also assessed whether G31P could antagonize CXCL8-dependent chemotaxis, ROI release by leukocytes, and intracellular Ca 2ϩ flux responses by purified human neutrophils using the same approaches as in A. C, To confirm that G31P also acted via the CXCR2, we tested its ability to antagonize neutrophil chemotactic and intracellular Ca 2ϩ flux responses induced by the CXCR2-exclusive ligands CXCL1 and CXCL5 (both 100 ng/ml). Our data confirm that G31P did effectively antagonize both CXCR1-and CXCR2-dependent responses. ‫ء‬ and ‫,ءء‬ p Ͻ 0.05 and 0.01, respectively, relative to the chemokine treatments alone. The data shown are representative of at least three experiments performed with similar results. The dashed lines across graphs in A-C represent the mean background response in the indicated assays. the asthmatic and COPD subjects also induced marked neutrophil responses, and G31P largely blocked these too; we have reported previously that sputum from asthmatic subjects contains high levels of CXCL8 (27) .
G31P blocks ELR-CXC chemokine-mediated antiapoptotic effects in neutrophils
As neutrophils leave the vasculature or become effete, they rapidly undergo programmed cell death or apoptosis as a means of preventing adventitious host pathology. However, during inflammatory events, it is in the best interest of the host to maintain these cells in a viable state such that they can effectively engage microbial targets. An array of inflammatory mediators, including the ELR-CXC chemokines, have antiapoptotic effects on neutrophils (31) . We wished to know then whether G31P's anti-inflammatory effects would extend to reversing chemokine-induced antiapoptotic processes, thereby allowing neutrophils to quickly progress into apoptosis. We used FITC-annexin V binding as our assay of apoptosis. We stained freshly purified neutrophils with this marker as a negative control (shaded signal; Fig. 4 ) and cells that had been cultured for 18 h in medium alone as an apoptosis-positive control (Fig. 4, upper panel) . The freshly purified cells appeared to have two levels of annexin binding, with most cells being more or less negative and a smaller proportion binding moderate levels of this apoptosis marker. When we added CXCL8 to the cells (Fig. 4 , middle panel, dashed line), there was a marked diminution of the numbers of cells that strongly bound annexin V, and the addition of G31P to these cultures fully reversed this CXCL8-induced antiapoptotic activity. CXCL1 also had protective effects on neutrophils, but they were subtly different from those of CXCL8 (Fig. 4,  bottom panel, dashed line) . The CXCL8-protected cells had largely bound intermediate levels of annexin V, whereas those incubated with CXCL1 bound either very low or intermediate levels of annexin. The addition of G31P to the CXCL1 cultures induced a substantial proportion of the cells to up-regulate their apoptotic processes, but nevertheless there remained a significant population of cells that bound intermediate levels of annexin.
G31P antagonizes the inflammatory cycle in endotoxin-challenged bronchial epithelial cells
Exposure of the airway epithelium to bacterial endotoxin triggers a pulmonary inflammatory response, wherein these cells secrete CXCL8, for example, which directly fosters neutrophil recruitment into this tissue compartment. Although we have shown that G31P antagonizes the impact of the ELR-CXC chemokines on neutrophil responses, little attention is paid to whether epithelial cells themselves respond to the ELR-CXC chemokines they elaborate in airway endotoxemia, or to the neutrophils they recruit. We thus decided to investigate this using human type II alveolar A549 epithelial cells that we challenged with bacterial endotoxin (Fig. 5)   FIGURE 3 . G31P antagonizes the neutrophil chemotactic activities present in sputum from CF and bronchiectasis patients with bacterial pneumonia. Sputum samples were collected from 12 CF or bronchiectasis patients with bacterial pneumonia as well as two control subjects with COPD or asthma, and assayed for their CXCL8 content (values above f). The abilities of G31P (10 ng/ml) to antagonize chemotactic responses of neutrophils from healthy donors to optimized dilutions of the sputa were assessed as in Fig. 1 . The data are expressed as the mean (ϮSEM) number of cells/ϫ40 objective microscope field. The assays were repeated twice and gave essentially the same results each time. Sputum from healthy donors did not induce any significant neutrophil chemotactic responses (data not shown). With the exception of samples 1 and 2, G31P significantly reduced the cells' chemotactic responses. ‫,ءء‬ p Յ 0.01 vs no G31P treatment. The dashed lines across the graph represent the mean background response in the assay. G31P engagement on neutrophils induces heterologous desensitization of their GPCR for C5a, LTB 4 , and fMLP. Purified human neutrophils were stimulated with 0.1 nM C5a, 1 nM fMLP, or 1 ng/ml LTB 4 , in the absence or presence of 10 or 50 ng/ml G31P, as described in Material and Methods. A, The ability of G31P (10 ng/ml) to interfere with the agonist-induced intracellular Ca 2ϩ flux was assessed as in Fig. 1. B , The abilities of varying doses of G31P to block the cells' chemotactic responses were also assessed as above. G31P very substantially reduced Ca 2ϩ flux induced by fMLP and LTB 4 , but was less effective in blocking C5a-dependent Ca 2ϩ flux, and this relative efficacy was observed also in the chemotaxis assays. in the presence or absence of G31P. The quiescent A549 cells secreted very little CXCL8, but LPS dose dependently up-regulated their expression of this chemokine. Reports of CXCR1 and CXCR2 expression by epithelial cells vary, so we wished first to determine whether our A549 cells expressed either of these receptors. We used quantitative real-time PCR and did indeed detect significant levels of the CXCR1 (Fig. 5A, right panel) , but little in the way of CXCR2. When we challenged our A549 cells with 10 ng/ml LPS in the presence of increasing doses of G31P, the cells produced progressively less CXCL8 (Fig. 5B ). This effect extended also to their expression of CXCL1, wherein G31P reduced LPS-induced CXCL1 expression by Ϸ98%, as determined by quantitative real-time PCR. Neutrophils release a variety of mediators that are potential epithelial cell agonists (e.g., elastase) (32), whereas epithelial cells similarly secrete neutrophil agonists. This suggests the possibility that these cells could through a putative mutual stimulatory mechanism drive an escalating inflammatory process. We tested this by coculturing purified otherwise quiescent neutrophils with monolayers of resting A549 cells. Although the neutrophils were largely unstimulated, there was a significant background release of CXCL8 by these cells over 16 h in culture (Fig. 6 ). Nevertheless, simple coculture of these neutrophils with A549 cells induced a synergistic expression of CXCL8 in the cultures, and this effect was dependent on the numbers of neutrophils added to the cultures (Fig. 6) . The A549 cells did not secrete significant amounts of CXCL8 when cultured on their own. The addition of G31P to these cocultures dramatically (up to 98%) reduced the expression of CXCL8 ( p Յ 0.01; Fig. 6 ). Necrotic cell death was also assessed by propidium iodide uptake; we found Յ3% propidium iodide-positive cells in all samples. The data indicate that cells incubated in medium alone were largely apoptotic. Exposure to CXCL8 or CXCL1 reduced apoptosis very substantially, but addition of G31P to these cultures largely reversed the ELR-CXC chemokine-induced antiapoptotic effects. These assays were repeated three times. 5 . G31P antagonizes the endotoxin-induced inflammatory cycle in human bronchial epithelial cells. A, Monolayers of A549 bronchial epithelial cells were exposed to varying doses of endotoxin, and the culture supernatant was collected 16 h later and assayed by ELISA for CXCL8 (left panel). Expression of the CXCR1 or CXCR2 by the A549 cells and human neutrophils was assessed by quantitative real-time PCR using specific primers (right panel). Our data indicate that peak CXCL8 expression was found in the A549 cultures that were challenged with 10 ng/ml LPS, and that our A549 cells expressed significant levels of CXCR1, although certainly much less than that found in neutrophils. B, A549 cell monolayers were challenged with 10 ng/ml LPS in the presence of the indicated concentrations of G31P, and 16 h later the culture supernatants and cellular RNA were isolated and assayed for CXCL8 protein (ELISA) and CXCL1 mRNA (quantitative real-time PCR). Addition of G31P to the A549 cells dose dependently suppressed expression of both chemokines by the LPSchallenged cells. ‫ء‬ and ‫,ءء‬ p Ͻ 0.05 and 0.01, respectively, relative to the baseline treatments alone. The data shown are representative of at least three experiments performed with similar results.
G31P blocks airway endotoxemia-induced acute lung inflammation
The observations that a fully human form of G31P blocked inflammatory responses at multiple levels (e.g., heterologous desensitization of GCPR, proapoptotic effects, blockade of the autocrine epithelial inflammatory cycle) suggested that it could be effective also in blocking inflammatory responses in vivo. We have shown that bovine and bovine-human chimeric orthologues of G31P can block an array of inflammatory pathologies, including airway endotoxemia (24, 25) , aspiration pneumonia (X. Zhao, J. Town, F. Li, W. Li, X. Zhang, and J. Gordon, submitted for publication), ischemia-reperfusion injury (X. Zhao, J. Town, A. Yang, X. Zhang, G. Sawicki, and J. Gordon, submitted for publication), and environmental pollutant-induced lung injury (33) . Although we know in airway endotoxemia that bG31P treatments reduce neutrophil infiltration of the airways, it remains possible that neutrophils marginate in the pulmonary vasculature under the influence of the inflammatory mediators expressed in this compartment and are activated in situ. For this reason, we wished to determine whether we could detect markers of the individual neutrophil granules or of activated structural cells in the lungs of endotoxemic animals. We induced airway endotoxemia in guinea pigs, as reported previously (24, 25) , and assessed the levels of MPO (1°g ranules), LF (2°granules), and MMP-9 (3°granules) at 4, 8, and 16 h after endotoxin challenge. We confirmed that G31P did indeed reduce airway neutrophilia (90 -99% reduced at 4, 8, and 16 h; p Յ 0.01 vs saline-treated animals). In concert with this, there were significant reductions in the BAL levels of MPO ( p Յ 0.05, 8-h time point only), LF ( p Յ 0.05, all times), and MMP-9 ( p Յ 0.05, 4-and 8-h time points), which suggested that few neutrophils that did achieve the lungs were not sufficiently activated to degranulate. We coincidentally observed a strong signal from a 68-kDa gelatinase (Fig. 7) that comigrated with MMP-2 expressed in positive control HT1080 fibrosarcoma cells (data not shown), suggesting that we had indeed strongly activated the lung epithelium and other structural cells that express this metalloproteinase (34, 35) . G31P treatment also essentially abrogated this response at each time, suggesting that, as we had observed with our A549 cells, structural cells were also influenced by ELR-CXC chemokine antagonism in vivo.
Discussion
We have generated a human orthologue of bG31P (36, 37) . We show in this study that this G31P specifically blocks activation of neutrophils through the CXCR1 and CXCR2, and thereby their chemoattraction into inflammatory foci and expression of ROI. In engineering bG31P from its parent molecule, bCXCL8, our first step was to introduce high affinity into the molecule, which we did by N-terminal truncation and substitution of a lysine in place of Arg 11 to generate bCXCL8 (3-73) K11R (23). These arguments were in part based on prior work with human CXCL8 by Clark-Lewis et al. (38, 39) , although the bovine form of CXCL8 K11R appeared to have unexpectedly high agonist activity relative to its closest human counterpart (23) . We next reduced the receptorsignaling activity of this agonist by introducing a Gly residue in place of Pro 31 to generate an antagonist that fortuitously had exceptionally high affinity relative to CXCL8 (22) . We hypothesize that it is this augmented receptor affinity that allows G31P to so effectively compete with native ELR-CXC chemokines for their receptors on neutrophils. It makes sense that G31P would operate via both the CXCR1 and CXCR2 because its parent molecule was CXCL8, a high-affinity ligand of both receptors (9, 40) . Our data showing that G31P blocks CXCL8-dependent intracellular Ca 2ϩ flux and chemotaxis in CXCR1-transfected HEK cells confirm unequivocally that G31P targets the CXCR1, and the fact that it blocks the activities of CXCL1 and CXCL5, which are exclusive FIGURE 6. Coculture of quiescent A549 cells with unstimulated peripheral blood neutrophils leads to synergistic CXCL8 expression. The indicated numbers of quiescent, purified human peripheral blood neutrophils from healthy donors were either cultured alone (PMN alone) or added to monolayers of unstimulated A549 cells (A549 ϩ PMN). G31P (100 ng/ml) was added to half of these cultures, and 16 h later the culture supernatants were harvested assayed for CXCL8 by ELISA. The addition of neutrophils to the A549 cells synergistically enhanced expression of CXCL8 in a cell concentration-dependent fashion, and G31P antagonized this cytokine response. ‫ء‬ and ‫,ءء‬ p Ͻ 0.05 and 0.01, respectively, relative to the no G31P treatments alone. The data shown are from one blood donor that is representative of the responses of three such donors. CXCR2 agonists (9, 40) , similarly confirms its interactions with these receptors.
We also documented in this study that G31P desensitizes heterologous GPCR in a quantitatively better fashion than CXCL8 (18) , probably in part because of its high-affinity interactions with CXCR1 and CXCR2 (22) . Thus, G31P blocked both intracellular Ca 2ϩ flux and chemotactic responses of neutrophils to signaling via CD88/C5aR1 (the C5a receptor), BLT1 (the LTB 4 receptor), and Fpr1 (the fMLP receptor), although it was not as effective in desensitizing C5a-dependent Ca 2ϩ flux as that associated with LTB 4 or fMLP signaling. It has been reported that in responding to signals generated in inflammatory settings, neutrophils adopt a hierarchical response pattern, with responsiveness to agonists immediately responsible for recruitment from the vasculature (e.g., CXCL8, LTB 4 ) being superceded as the cells traverse the blood vessel wall by responsiveness to those that would draw the cell to the pathogen itself (e.g., C5a, fMLP) (41) . This effect is reportedly brought about by C5a-and fMLP-driven activation of MAPK in neutrophils, which dampens Akt activation, a critical event in responses to CXCL8 and LTB 4 (41) . In the context of a bacterial infection, for example, this process would make a great deal of sense, because as the neutrophil moves into the tissues and toward the pathogen, it must necessarily concentrate its resources on that target. In support of this, it had also been reported that whereas the fMLP and C5a receptors can cross-desensitize one another and the CXCL8 receptor, CXCL8 signaling cannot reciprocally desensitize Ca 2ϩ flux or a number of other intracellular events downstream of the fMLP or C5a receptors (19, 20) . At odds with this, however, is the report that whereas the CXCR2 cannot desensitize the CD88 or Fpr1, CXCR1 signaling can do so, albeit at significantly lower levels than that seen with C5a or fMLP-induced CXCL8 receptor desensitization (42) . Also at odds is the report that CXCL8 signaling desensitizes neutrophil chemotactic responses to subsequent C5a or fMLP exposures (18) . Our own data clearly indicated that G31P desensitizes neutrophil responses to fMLP, C5a, and LTB 4 , as noted most likely related to high-affinity interactions with its receptors. This could in part explain its effectiveness in dampening the pathology associated with airway endotoxemia in our model. It is known that endotoxin activates C5 to generate C5a (43), and it seems reasonable to suggest that commercial endotoxin preparations such as we used would likely be contaminated with bacterial tripeptides (e.g., fMLP). Furthermore, given that LTB 4 antagonism is of significant benefit in airway endotoxemia (17, 44) , it is also reasonable to suggest that this agonist would also have been present in our endotoxemic animals, although we did not assess this. This suggests that the neutrophilic pathology we observed could well be related to the combined effects of multiple agonists, including ELR-CXC chemokines, C5a, LTB 4 , and perhaps fMLP. We hypothesize that the ability of G31P to ameliorate this pathology is attributable to its ability to not only block the CXCR1 and CXCR2, but also desensitize these other GPCR.
Another important finding in this study was that G31P also antagonized the responses of airway epithelial cells to bacterial endotoxin. Our data show that A549 cells express the CXCR1, although epithelial expression of the CXCR1 or CXCR2 is not uniform. Although unstimulated BEAS2B or colonic epithelial cells do not express the CXCR-1 or CXCR-2 (45, 46) , epithelial cell lines from CF patients (IB3-1 and CFBE41o-) do express these receptors (47) . In contrast, hypoxic Caco-2 and HT-29 bronchial epithelial cells express the CXCR1 (but not the CXCR2) and undergo chemotactic responses to CXCL8 signaling (48) . This could suggest that inflammatory signals up-regulate expression of these receptors, but in A549 cells, at least, LPS stimulation does not alter their expression of the CXCR1 or CXCR2 (J. Town, unpublished observation). The blockade of CXCL8 expression in LPS-stimulated epithelial cells by G31P leads us to speculate that CXCR1 ligands are autocrine inflammatory mediators for these cells. It had been reported previously that CXCL8 is an autocrine growth factor for pancreatic tumor (49) and melanoma (50, 51) cells, but, as far as we are aware, this is the first demonstration that ELR-CXC chemokine expression can be a self-perpetuating event for epithelial cells. We also found that simple coculture of quiescent human neutrophils with A549 cells strongly induced CXCL8 expression in these cultures and that G31P interrupts this response, dramatically reducing chemokine production. We did not determine which population of cells was activated in these cocultures, and therefore, responsible for the cytokine expression. A number of mediators released from activated neutrophils (e.g., cathepsin G, elastase, defensins) can induce the release of CXCL8 from respiratory epithelial cells and, reciprocally, a number of epithelial products are neutrophil agonists (52, 53) . Although neutrophils can be readily activated by the procedures used in their isolation (54, 55) , when cultured alone neither the epithelial cells or neutrophils secreted substantial amounts of CXCL8, indicating that the interactions between these two cells were instrumental in their induction, and that endotoxin contamination of our culture medium by itself would not explain our observations. More importantly, G31P was able to interfere with these intercellular interactions sufficiently to ameliorate their influence on one another. The remarkable degree to which G31P dampened neutrophilic inflammation in our airway endotoxemic animals suggests that its ability to block the interactions between bronchial epithelial cells and those neutrophils that did find their way into the airways could be another integral component of its therapeutic effects.
Neutrophils are continuously generated in the bone marrow and released into the circulation at exceptionally high rates, which means of course that they need to be equally quickly disposed of if a homeostatic balance is to be maintained. Thus, neutrophils are preprogrammed to undergo apoptotic death quite rapidly, and this is only offset if inflammatory events dictate that there is an extended need for increased numbers of viable cells. A number of inflammatory mediators have antiapoptotic effects on neutrophils, including the ELR-CXC chemokines (31, 56) , such that cells exposed to these mediators remain viable for extended periods of time, and thereby can potentially contribute to the regional antimicrobial activities. This translates also into potential contributions to adventitious pathogenic processes, such that the ability of G31P to countermand ELR-CXC chemokine-driven antiapoptotic effects would be of significant benefit to the host by virtue of encouraging functional removal of these cells from the inflammatory environment.
We had previously shown that bovine and a human-bovine chimeric form of G31P are effective in blocking neutrophilic pathology associated with airway endotoxemia (24, 25) , and we confirmed in this study for the first time that the human orthologue G31P was similarly effective. In this study, we assessed the kinetics of neutrophil infiltration of the airways as well as their activation in situ in the lungs. Our data showed that G31P can dramatically reduce neutrophil recruitment and activation, inasmuch as we found high levels of the primary, secondary, and tertiary granule markers MPO, LF, and MMP-9, respectively, in lungs of the saline-treated endotoxemic animals, but not in the G31P-treated animals. Previous studies have shown that a number of MMP are present in the airways during experimental or clinical acute lung injuries or respiratory distress (34, 35) , and we found both MMP-2 and MMP-9 in our BAL samples. Although one might argue that the multiple gelatinases detected in our zymograms (i.e., 92 and 68 kDa) could have been attributable to processing of high m.w.
MMP-9 to smaller forms, such processing of MMP-9 reportedly leads to generation of 86-and 82-kDa gelatinases (i.e., not a 68-kDa activity) (57) . MMP-2 is expressed as a 72-kDa zymogen that is processed to a 68-kDa gelatinase (58) . MMP-2 is mainly produced by resident cells during acute lung injury, including, for example, type II epithelial cells or endothelial cells (35) , such that the observation that G31P blocked its expression further supports our hypothesis that this antagonist acts not only on the neutrophil, but also on epithelial or other resident cells. Endothelial cells, another source of MMP-2 (35) , also express the CXCR2 (59), so could potentially also fall under the influence of G31P.
In conclusion, our data indicate that G31P is a potent antagonist of neutrophil activation induced by ELR-CXC chemokines. It targets not only the CXCR1 and CXCR2, but also heterologous GPCR (e.g., CD88/C5aR1, BLT1, and Fpr1) expressed on CXCR1-or CXCR2-positive cells, and it interrupts the autocrine epithelial cell inflammatory cascade triggered by bacterial endotoxins. Thus, the beneficial effects of G31P flow from its ability to simultaneously target multiple inflammatory processes. We speculate that the ability of G31P to antagonize heterologous GPCR may be a very important part of its anti-inflammatory activities, such that ELR-CXC chemokine antagonism in the absence of such activities (e.g., by anti-chemokine Abs) may provide somewhat less effective protection. An obvious question to ask when one wishes to block neutrophil participation in biological responses is whether there are deleterious effects. For example, in bacterial pneumonia, one might expect that these cells may be required for successful elimination of the pathogen(s). However, we have found that G31P very significantly attenuates pathology in aspiration pneumonia, but at the same time does not reduce control of the microbial populations that enter the airways (X. Zhao, J. Town, F. Li, W. Li, X. Zhang, and J. Gordon, submitted for publication). Blocking neutrophil recruitment in bovine pneumonic pasteurellosis similarly improves outcomes very significantly (60) . We would predict based on our cumulative results that a broad array of inflammatory diseases would thus benefit from such ELR-CXC chemokine antagonism, as might other processes in which inflammation per se is not necessarily prevalent, but in which the ELR-CXC chemokines have nevertheless been implicated.
